United States Breaking News

Sagimet Biosciences (NASDAQ:SGMT) reported 52-week denifanstat acne results from license partner Ascletis’ Phase 3 extension study, including 57% Investigator’s Global Assessment success.

Profound Medical (NASDAQ:PROF) entered a co-education agreement with Telix Pharmaceuticals to support physician education on imaging-informed prostate care.

Col. Wayne Sanders (Ret.) of Bloomberg Intelligence examines what he calls the "hornet's nest" of increased activity in the Middle East as President Donald Trump said Thursday that the US would not strike Iran before the midterm elections.

Arcutis Biotherapeutics (NASDAQ:ARQT) presented new ZORYVE clinical data in infants with atopic dermatitis and patients with psoriasis at EADV and Fall Clinical.

Teva Pharmaceutical Industries (NYSE:TEVA) received U.S. Food and Drug Administration approval for WELTRUZA, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia.

Valion Bio (NASDAQ:VBIO) and Shear Kershman Laboratories completed formulation work on an oral mucosal version of Entolimod for potential use in radiation emergencies.

Glaukos (NYSE:GKOS) reported positive topline Phase 4 results showing iDose TR plus cataract surgery reduced mean diurnal intraocular pressure by 11.1 mmHg from baseline at Month 3.

Seaport Therapeutics (NASDAQ:SPTX) presented Phase 1 GlyphAgo data showing a statistically significant 6.8-fold increase in agomelatine bioavailability compared with unmodified agomelatine.

SpaceX (NASDAQ:SPCX) announced an agreement to acquire a nationwide low-band spectrum license portfolio, sending T-Mobile (NASDAQ:TMUS), AT&T (NYSE:T) and Verizon (NYSE:VZ) lower in premarket trading.

Chris Verrone, partner and chief market strategist at Baird Strategas, sees equity markets as "highly rotational" and doesn't think bond yields are high enough to be "truly competitive for your capital every day." He speaks on "Bloomberg Surveillance."

MINISO Group (NYSE:MNSO) reported preliminary mainland China gross merchandise value growth of 25%–30% year over year for the third quarter of 2026.

Aura Minerals (NASDAQ:AUGO) reported preliminary record third-quarter 2026 production of 95,557 gold equivalent ounces, up 29% from a year earlier at current prices.